# 2026-12842: NIH Invents Omega-3 Boosted Cancer Vaccines

2026-12842, Government Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacy, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-06-25; PRIA reads it as touching household money (as of 2026-07-02).

- Canonical: https://policyrisk.com/federal-register/2026-12842
- As of: 2026-07-02
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12842
- Title: Government Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacy
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 38451
- Published: 2026-06-25
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-02

## In one line

NIH Invents Omega-3 Boosted Cancer Vaccines

## Summary

The National Cancer Institute has created a new way to make cancer vaccines stronger by using special omega-3 fats to boost immune cells called dendritic cells. This could help scientists and companies develop better cancer treatments that work more effectively. If you’re in biotech or medicine, now’s the time to team up or license this exciting technology and help bring improved vaccines to patients faster.

## Abstract

The National Cancer Institute (NCI) is seeking research co- development partners and/or licensees for NCI's compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.

## Effects PRIA read

- NCI Offers Licensing for Omega‑3 DC Vaccine Tech: benefit, medium. The National Cancer Institute is offering its compositions and methods that use omega‑3 fatty acids (DHA and EPA) or pro‑resolving lipid mediators to boost dendritic cell (DC) cancer vaccine effectiveness for licensing or co‑development. The technology is at a pre‑clinical stage (in vivo validation…

## Related documents

- [2026-20705](https://policyrisk.com/federal-register/2026-20705): Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With…, 2026-10-09
- [2026-20771](https://policyrisk.com/federal-register/2026-20771): Center for Scientific Review; Notice of Closed Meetings, 2026-10-09
- [2026-20424](https://policyrisk.com/federal-register/2026-20424): National Cancer Institute; Notice of Meeting, 2026-10-06
- [2026-20365](https://policyrisk.com/federal-register/2026-20365): Center For Scientific Review; Notice of Closed Meetings, 2026-10-05
- [2026-20151](https://policyrisk.com/federal-register/2026-20151): Notice of NIH Tribal Consultations and Listening Session, 2026-10-01
- [2026-19718](https://policyrisk.com/federal-register/2026-19718): Center for Scientific Review; Notice of Closed Meetings, 2026-09-28

## Sources
- [2026-12842 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/25/2026-12842/government-owned-inventions-available-for-license-compositions-and-methods-for-producing-dendritic)
- [2026-12842 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-25/pdf/2026-12842.pdf)

## Related
- [Previous: 2026-12835, Agency Information Collection Activities; Notice and Request for Comment; Intel…](https://policyrisk.com/federal-register/2026-12835)
- [Next: 2026-12843, Government Owned Inventions Available for License: C8166-45 Cell Line](https://policyrisk.com/federal-register/2026-12843)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12842 (as of 2026-07-02).